Skip to main content

CORRECTION article

Front. Pharmacol., 29 August 2024
Sec. Neuropharmacology
Volume 15 - 2024 | https://doi.org/10.3389/fphar.2024.1464358

Corrigendum: Effect of a high dose atorvastatin as added-on therapy on symptoms and serum AMPK/NLRP3 inflammasome and IL-6/STAT3 axes in patients with major depressive disorder: randomized controlled clinical study

This article is a correction to:

  1. Effect of a high dose atorvastatin as added-on therapy on symptoms and serum AMPK/NLRP3 inflammasome and IL-6/STAT3 axes in patients with major depressive disorder: randomized controlled clinical study

    1. Read original article
Khlood Mohammad AldossaryKhlood Mohammad Aldossary1Lashin Saad Ali,Lashin Saad Ali2,3Mahmoud S. Abdallah,Mahmoud S. Abdallah4,5Mostafa M. Bahaa Mostafa M. Bahaa6*Thanaa A. ElmasryThanaa A. Elmasry7Eman I. ElberriEman I. Elberri8Fedaa A. KotkataFedaa A. Kotkata8Ramy M. El SabaaRamy M. El Sabaa9Yasmine M. ElmorsiYasmine M. Elmorsi8Mostafa M. KamelMostafa M. Kamel10Walaa A. NegmWalaa A. Negm11Aya Ibrahim ElberriAya Ibrahim Elberri12Amir O. HamoudaAmir O. Hamouda13Hayam Ali AlRasheedHayam Ali AlRasheed1Muhammed M. SalahuddinMuhammed M. Salahuddin13Mohamed Yasser,Mohamed Yasser14,15Manal A. HamoudaManal A. Hamouda9
  • 1Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia
  • 2Department of Basic Medical Science, Faculty of Dentistry, Al-Ahliyya Amman University, Amman, Jordan
  • 3Physiology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
  • 4Department of Clinical Pharmacy, Faculty of Pharmacy, University of Sadat City (USC), Sadat City, Menoufia, Egypt
  • 5Department of PharmD, Faculty of Pharmacy, Jadara University, Irbid, Jordan
  • 6Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt
  • 7Pharmacology and Toxicology Department, Faculty of Pharmacy, Tanta University, Tanta, Al-Gharbia, Egypt
  • 8Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Al-Gharbia, Egypt
  • 9Department of Clinical Pharmacy, Faculty of Pharmacy, Menoufia University, Shebin El-Kom, Menoufia, Egypt
  • 10Psychiatry Department, Faculty of Medicine, Tanta University, Egypt
  • 11Pharmacognosy Department, Faculty of Pharmacy, Tanta University, Tanta, Al-Gharbia, Egypt
  • 12Genetic Engineering and Molecular Biology Division, Department of Zoology, Faculty of Science, Menoufia University, Shebin El-Kom, Menoufia, Egypt
  • 13Department of Biochemistry and Pharmacology, Faculty of Pharmacy, Horus University, New Damietta, Egypt
  • 14Department of Pharmaceutics, Faculty of Pharmacy, Port Said University, Port Said, Egypt
  • 15Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Horus University, New Damietta, Egypt

A Corrigendum on
Effect of a high dose atorvastatin as added-on therapy on symptoms and serum AMPK/NLRP3 inflammasome and IL-6/STAT3 axes in patients with major depressive disorder: randomized controlled clinical study

by Aldossary KM, Ali LS, Abdallah MS, Bahaa MM, Elmasry TA, Elberri EI, Kotkata FA, El Sabaa RM, Elmorsi YM, Kamel MM, Negm WA, Elberri AI, Hamouda AO, AlRasheed HA, Salahuddin MM, Yasser M and Hamouda MA (2024). Front. Pharmacol. 15:1381523. doi: 10.3389/fphar.2024.1381523

In the published article, there was an error regarding the Affiliation for Manal A. Hamouda. Instead of having the affiliation “7 Pharmacology and Toxicology Department, Faculty of Pharmacy, Tanta University, Tanta, Al-Gharbia, Egypt,” they should be affiliated with “9 Department of Clinical Pharmacy, Faculty of Pharmacy, Menoufia University, Shebin El-Kom, Menoufia, Egypt.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: atorvastatin, major depressive disorder, neuroinflammation, NLRP-3, STAT-3

Citation: Aldossary KM, Saad Ali L, Abdallah MS, Bahaa MM, Elmasry TA, Elberri EI, Kotkata FA, El Sabaa RM, Elmorsi YM, Kamel MM, Negm WA, Elberri AI, Hamouda AO, AlRasheed HA, Salahuddin MM, Yasser M and Hamouda MA (2024) Corrigendum: Effect of a high dose atorvastatin as added-on therapy on symptoms and serum AMPK/NLRP3 inflammasome and IL-6/STAT3 axes in patients with major depressive disorder: randomized controlled clinical study. Front. Pharmacol. 15:1464358. doi: 10.3389/fphar.2024.1464358

Received: 13 July 2024; Accepted: 20 August 2024;
Published: 29 August 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Aldossary, Saad Ali, Abdallah, Bahaa, Elmasry, Elberri, Kotkata, El Sabaa, Elmorsi, Kamel, Negm, Elberri, Hamouda, AlRasheed, Salahuddin, Yasser and Hamouda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Mostafa M. Bahaa, mbahaa@horus.edu.eg

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.